Several Companies Highlight Upcoming Presentations At American Society Of Clinical Oncology Meeting Jun. 3-7: Provectus, Advaxis, Adicet Bio, Cullinan Oncology, Galera, BeiGene, Arcellx, PDS Biotech, Tempest, Karyopharm

4/27/22 10:02:45 AM ET

$ACET

$ACLX

$ADXS

$BGNE

Biotechnology: Pharmaceutical Preparations

Health Care

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

Get the next $ACET alert in real time by email

Several Companies Highlight Upcoming Presentations At American Society Of Clinical Oncology Meeting Jun. 3-7: Provectus, Advaxis, Adicet Bio, Cullinan Oncology, Galera, BeiGene, Arcellx, PDS Biotech, Tempest, Karyopharm

Get the next $ACET alert in real time by email

Crush Q1 2026 with the Best AI Superconnector

Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

AI-Powered Inbox

Context-aware email replies

Strategic Decision Support

Get Started with Standout.work

Recent Analyst Ratings for
$ACET
$ACLX
$ADXS
$BGNE

Company	Date	Price Target	Rating	Analyst
Cullinan Therapeutics Inc. $CGEM	2/17/2026	$33.00	Buy	Citigroup
Arcellx Inc. $ACLX	2/12/2026	$82.00	Buy → Neutral	Rothschild & Co Redburn
Cullinan Therapeutics Inc. $CGEM	2/2/2026	$30.00	Buy	Guggenheim
Arcellx Inc. $ACLX	1/7/2026	$100.00	Buy	UBS
Arcellx Inc. $ACLX	12/22/2025	$100.00	Overweight	Wells Fargo
Arcellx Inc. $ACLX	11/18/2025		Peer Perform	Wolfe Research
Arcellx Inc. $ACLX	10/16/2025	$129.00	Buy	Stifel
Cullinan Therapeutics Inc. $CGEM	8/21/2025	$24.00	Buy	H.C. Wainwright

More analyst ratings

Several Companies Highlight Upcoming Presentations At American Society Of Clinical Oncology Meeting Jun. 3-7: Provectus, Advaxis, Adicet Bio, Cullinan Oncology, Galera, BeiGene, Arcellx, PDS Biotech, Tempest, Karyopharm

Crush Q1 2026 with the Best AI Superconnector

Recent Analyst Ratings for
$ACET
$ACLX
$ADXS
$BGNE

Several Companies Highlight Upcoming Presentations At American Society Of Clinical Oncology Meeting Jun. 3-7: Provectus, Advaxis, Adicet Bio, Cullinan Oncology, Galera, BeiGene, Arcellx, PDS Biotech, Tempest, Karyopharm

Crush Q1 2026 with the Best AI Superconnector

Recent Analyst Ratings for
$ACET
$ACLX
$ADXS
$BGNE

$ACET
$ACLX
$ADXS
$BGNE
SEC Filings

Amendment: SEC Form SC 14D9/A filed by Arcellx Inc.

Amendment: SEC Form SC TO-T/A filed by Arcellx Inc.

SEC Form 425 filed by Galera Therapeutics Inc.

$ACET
$ACLX
$ADXS
$BGNE
Insider Purchases

Large owner Lynx1 Capital Management Lp bought $1,391,686 worth of shares (165,667 units at $8.40) (SEC Form 4)

Large owner Lynx1 Capital Management Lp bought $114,048 worth of shares (15,032 units at $7.59) and bought $1,989,864 worth of shares (233,717 units at $8.51) (SEC Form 4)

Large owner Orbimed Advisors Llc bought $5,000,000 worth of shares (5,000,000 units at $1.00) (SEC Form 4)

$ACET
$ACLX
$ADXS
$BGNE
Insider Trading

SEC Form 4 filed by Gilson Michelle

SEC Form 4 filed by Ra Capital Management, L.P.

SEC Form 3 filed by new insider Ra Capital Management, L.P.

$ACET
$ACLX
$ADXS
$BGNE
Analyst Ratings

Citigroup initiated coverage on Cullinan Therapeutics with a new price target

Arcellx downgraded by Rothschild & Co Redburn with a new price target

Guggenheim initiated coverage on Cullinan Therapeutics with a new price target

$ACET
$ACLX
$ADXS
$BGNE
Press Releases

Galera Therapeutics and Obsidian Therapeutics Announce Merger Agreement and $350 Million Concurrent Private Placement

Obsidian Therapeutics and Galera Therapeutics Announce Merger Agreement and $350 Million Concurrent Private Placement

Adicet Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Company Progress

$ACET
$ACLX
$ADXS
$BGNE
Financials

Cullinan Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2025 Financial Results

Adicet Bio Announces Positive Preliminary Data from ADI-001 Phase 1 Study in Patients with Lupus Nephritis (LN) and Systemic Lupus Erythematosus (SLE)

Cullinan Therapeutics Provides Corporate Update and Reports Second Quarter 2025 Financial Results

$ACET
$ACLX
$ADXS
$BGNE
Large Ownership Changes

Amendment: SEC Form SC 13D/A filed by BeiGene Ltd.

Amendment: SEC Form SC 13D/A filed by BeiGene Ltd.

SEC Form SC 13G filed by Arcellx Inc.

$ACET
$ACLX
$ADXS
$BGNE
Leadership Updates

Adicet Bio Appoints Michael Grissinger to the Board of Directors

Arcellx Appoints Andrew Galligan and Kristin Myers to Its Board of Directors

OS Therapies Agrees to Acquire All Listeria Monotygenes-based Immuno-Oncology Programs and IP Assets from Ayala Pharmaceuticals, Adding Phase 2 Lung Cancer and Phase 1 Prostrate Cancer Programs to Pipeline

Several Companies Highlight Upcoming Presentations At American Society Of Clinical Oncology Meeting Jun. 3-7: Provectus, Advaxis, Adicet Bio, Cullinan Oncology, Galera, BeiGene, Arcellx, PDS Biotech, Tempest, Karyopharm

Crush Q1 2026 with the Best AI Superconnector

Recent Analyst Ratings for $ACET$ACLX$ADXS$BGNE

Several Companies Highlight Upcoming Presentations At American Society Of Clinical Oncology Meeting Jun. 3-7: Provectus, Advaxis, Adicet Bio, Cullinan Oncology, Galera, BeiGene, Arcellx, PDS Biotech, Tempest, Karyopharm

Crush Q1 2026 with the Best AI Superconnector

Recent Analyst Ratings for $ACET$ACLX$ADXS$BGNE

$ACET$ACLX$ADXS$BGNE SEC Filings

Amendment: SEC Form SC 14D9/A filed by Arcellx Inc.

Amendment: SEC Form SC TO-T/A filed by Arcellx Inc.

SEC Form 425 filed by Galera Therapeutics Inc.

$ACET$ACLX$ADXS$BGNE Insider Purchases

Large owner Lynx1 Capital Management Lp bought $1,391,686 worth of shares (165,667 units at $8.40) (SEC Form 4)

Large owner Lynx1 Capital Management Lp bought $114,048 worth of shares (15,032 units at $7.59) and bought $1,989,864 worth of shares (233,717 units at $8.51) (SEC Form 4)

Large owner Orbimed Advisors Llc bought $5,000,000 worth of shares (5,000,000 units at $1.00) (SEC Form 4)

$ACET$ACLX$ADXS$BGNE Insider Trading

SEC Form 4 filed by Gilson Michelle

SEC Form 4 filed by Ra Capital Management, L.P.

SEC Form 3 filed by new insider Ra Capital Management, L.P.

$ACET$ACLX$ADXS$BGNE Analyst Ratings

Citigroup initiated coverage on Cullinan Therapeutics with a new price target

Arcellx downgraded by Rothschild & Co Redburn with a new price target

Guggenheim initiated coverage on Cullinan Therapeutics with a new price target

$ACET$ACLX$ADXS$BGNE Press Releases

Galera Therapeutics and Obsidian Therapeutics Announce Merger Agreement and $350 Million Concurrent Private Placement

Obsidian Therapeutics and Galera Therapeutics Announce Merger Agreement and $350 Million Concurrent Private Placement

Adicet Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Company Progress

$ACET$ACLX$ADXS$BGNE Financials

Cullinan Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2025 Financial Results

Adicet Bio Announces Positive Preliminary Data from ADI-001 Phase 1 Study in Patients with Lupus Nephritis (LN) and Systemic Lupus Erythematosus (SLE)

Cullinan Therapeutics Provides Corporate Update and Reports Second Quarter 2025 Financial Results

$ACET$ACLX$ADXS$BGNE Large Ownership Changes

Amendment: SEC Form SC 13D/A filed by BeiGene Ltd.

Amendment: SEC Form SC 13D/A filed by BeiGene Ltd.

SEC Form SC 13G filed by Arcellx Inc.

$ACET$ACLX$ADXS$BGNE Leadership Updates

Adicet Bio Appoints Michael Grissinger to the Board of Directors

Arcellx Appoints Andrew Galligan and Kristin Myers to Its Board of Directors

OS Therapies Agrees to Acquire All Listeria Monotygenes-based Immuno-Oncology Programs and IP Assets from Ayala Pharmaceuticals, Adding Phase 2 Lung Cancer and Phase 1 Prostrate Cancer Programs to Pipeline

Recent Analyst Ratings for
$ACET
$ACLX
$ADXS
$BGNE

Recent Analyst Ratings for
$ACET
$ACLX
$ADXS
$BGNE

$ACET
$ACLX
$ADXS
$BGNE
SEC Filings

$ACET
$ACLX
$ADXS
$BGNE
Insider Purchases

$ACET
$ACLX
$ADXS
$BGNE
Insider Trading

$ACET
$ACLX
$ADXS
$BGNE
Analyst Ratings

$ACET
$ACLX
$ADXS
$BGNE
Press Releases

$ACET
$ACLX
$ADXS
$BGNE
Financials

$ACET
$ACLX
$ADXS
$BGNE
Large Ownership Changes

$ACET
$ACLX
$ADXS
$BGNE
Leadership Updates